Drug intelligence / Profile preview

RVL-069

Development stage: Preclinical
Lead developer: Unravel Biosciences
Modality: Small Molecules

Overview

RVL-069 is a preclinical-stage small molecule therapeutic candidate developed by Unravel Biosciences for the treatment of demyelinating diseases. The compound was identified using Unravel's proprietary BioNAV platform, which integrates clinical data and artificial intelligence to discover novel therapeutic targets and drug candidates. While the specific molecular target and mechanism of action for RVL-069 have not been publicly disclosed, the program is designed to address pathologies involving the loss or damage of myelin, such as multiple sclerosis or leukodystrophies.

Other names: RVL-069RVL069RVL 069

Beyond the preview

Go deeper on RVL-069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVL-069.

Explore the full profile